Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C

Andres F. Carrion, Paul Martin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: The combination of elbasvir and grazoprevir in a single co-formulated tablet is highly effective for treatment of hepatitis C virus (HCV) infection. This regimen affords profound inhibition of NS3/4A protease and NS5A activity, resulting in potent activity against HCV genotypes 1, 4, and 6 with high rates of sustained virological response. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy and safety profile of elbasvir/grazoprevir including special populations such as individuals with compensated and decompensated cirrhosis, HCV/HIV co-infection, advanced chronic kidney disease, and those that previously failed antiviral therapy. Expert opinion: Elbasvir/grazoprevir is an effective antiviral regimen for treatment of genotypes 1 and 4 and has a very favorable safety profile based on extensive data from several pre-licensure clinical trials that included patient subgroups at increased risk of toxicity. This regimen is currently the only one licensed for use in individuals with advanced chronic kidney disease requiring hemodialysis.

Original languageEnglish (US)
Pages (from-to)883-890
Number of pages8
JournalExpert Opinion on Drug Safety
Volume15
Issue number6
DOIs
StatePublished - Jun 2 2016

Fingerprint

Hepatitis C
Hepacivirus
Chronic Renal Insufficiency
Safety
Antiviral Agents
Genotype
Expert Testimony
Virus Diseases
Licensure
Coinfection
Tablets
HIV Infections
Renal Dialysis
Fibrosis
Peptide Hydrolases
Therapeutics
Pharmacokinetics
Clinical Trials
Population
2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole

Keywords

  • adverse reactions
  • antiviral therapy
  • chronic kidney disease
  • cirrhosis
  • Hepatitis C
  • HIV
  • toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. / Carrion, Andres F.; Martin, Paul.

In: Expert Opinion on Drug Safety, Vol. 15, No. 6, 02.06.2016, p. 883-890.

Research output: Contribution to journalArticle

@article{67a94663ab814b5588e0061e0cead589,
title = "Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C",
abstract = "Introduction: The combination of elbasvir and grazoprevir in a single co-formulated tablet is highly effective for treatment of hepatitis C virus (HCV) infection. This regimen affords profound inhibition of NS3/4A protease and NS5A activity, resulting in potent activity against HCV genotypes 1, 4, and 6 with high rates of sustained virological response. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy and safety profile of elbasvir/grazoprevir including special populations such as individuals with compensated and decompensated cirrhosis, HCV/HIV co-infection, advanced chronic kidney disease, and those that previously failed antiviral therapy. Expert opinion: Elbasvir/grazoprevir is an effective antiviral regimen for treatment of genotypes 1 and 4 and has a very favorable safety profile based on extensive data from several pre-licensure clinical trials that included patient subgroups at increased risk of toxicity. This regimen is currently the only one licensed for use in individuals with advanced chronic kidney disease requiring hemodialysis.",
keywords = "adverse reactions, antiviral therapy, chronic kidney disease, cirrhosis, Hepatitis C, HIV, toxicity",
author = "Carrion, {Andres F.} and Paul Martin",
year = "2016",
month = "6",
day = "2",
doi = "10.1080/14740338.2016.1179278",
language = "English (US)",
volume = "15",
pages = "883--890",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C

AU - Carrion, Andres F.

AU - Martin, Paul

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Introduction: The combination of elbasvir and grazoprevir in a single co-formulated tablet is highly effective for treatment of hepatitis C virus (HCV) infection. This regimen affords profound inhibition of NS3/4A protease and NS5A activity, resulting in potent activity against HCV genotypes 1, 4, and 6 with high rates of sustained virological response. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy and safety profile of elbasvir/grazoprevir including special populations such as individuals with compensated and decompensated cirrhosis, HCV/HIV co-infection, advanced chronic kidney disease, and those that previously failed antiviral therapy. Expert opinion: Elbasvir/grazoprevir is an effective antiviral regimen for treatment of genotypes 1 and 4 and has a very favorable safety profile based on extensive data from several pre-licensure clinical trials that included patient subgroups at increased risk of toxicity. This regimen is currently the only one licensed for use in individuals with advanced chronic kidney disease requiring hemodialysis.

AB - Introduction: The combination of elbasvir and grazoprevir in a single co-formulated tablet is highly effective for treatment of hepatitis C virus (HCV) infection. This regimen affords profound inhibition of NS3/4A protease and NS5A activity, resulting in potent activity against HCV genotypes 1, 4, and 6 with high rates of sustained virological response. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy and safety profile of elbasvir/grazoprevir including special populations such as individuals with compensated and decompensated cirrhosis, HCV/HIV co-infection, advanced chronic kidney disease, and those that previously failed antiviral therapy. Expert opinion: Elbasvir/grazoprevir is an effective antiviral regimen for treatment of genotypes 1 and 4 and has a very favorable safety profile based on extensive data from several pre-licensure clinical trials that included patient subgroups at increased risk of toxicity. This regimen is currently the only one licensed for use in individuals with advanced chronic kidney disease requiring hemodialysis.

KW - adverse reactions

KW - antiviral therapy

KW - chronic kidney disease

KW - cirrhosis

KW - Hepatitis C

KW - HIV

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84965062863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965062863&partnerID=8YFLogxK

U2 - 10.1080/14740338.2016.1179278

DO - 10.1080/14740338.2016.1179278

M3 - Article

C2 - 27091555

AN - SCOPUS:84965062863

VL - 15

SP - 883

EP - 890

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -